We report a case involving an obese patient with type 2 diabetes and dilated cardiomyopathy, in which the long-term improvement of left ventricular contractility was observed after the administration of empagliflozin. The patient was a 45-year-old man. He developed heart failure at 30 years of age and was diagnosed with dilated cardiomyopathy. He developed type 2 diabetes at 33 years of age and was treated with an oral hypoglycemic drug; however, empagliflozin (10 mg) was started due to poor glycemic control. The patient's glycemic control improved and weight loss was noted. Before the start of empagliflozin, the left ventricular diastolic dimension (LVDd) was 55.5 mm, the left ventricular systolic dimension (LVDs) was 41.0 mm, and the left ventricular ejection fraction (LVEF) was 48.1 %, as measured by echocardiography. After 4 years and 7 months, the LVDd was 46.5 mm, the LVDs was 29.8 mm, and the LVEF was 65.6 %. This was an extremely rare case in which long-term improvement in left ventricular contractility was obtained after the administration of empagliflozin. It is a very suggestive and valuable case for observing the effect of SGLT2 inhibitors on left ventricular contractility.